McKesson, Blue Cross top digital health’s most trusted corporate VCs
Part II in our research examining which corporate venture capitalists you can trust and rely on.
Part II in our research examining which corporate venture capitalists you can trust and rely on.
StartUp Health is looking for more business to business models covering virtual care, payments in new Startup Health Academy class.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The interest in adopting digital health tools such as clinical wearables and smartphone diagnostics has been hindered in some ways by the rapid growth in the number of these devices and relatively little clinical validation. GE Ventures and Stanford Health Care have partnered to launch a company called Evidation Health to validate and optimize digital […]
Healthcare data analytics company Aver Informatics thinks the next generation of healthcare reimbursement lies in bundled payments, and now Drive Capital and GE Ventures have backed up that hypothesis too. The investors led an $8.5 million Series A that will allow the startup to expand its engineering and sales teams and accelerate growth, execs said. […]
Corporate venture capital investments in healthcare hit a five-quarter low in Q3, down in both deals and funding, according to a new report out from CB Insights. Compared to the quarter before, deals and funding decreased by 41 percent and 27 percent respectively. The tried-and-true players fared well: California, Massachusetts and Minnesota grabbed the CVC […]
Boston Scientific (BSX) announced it has received U.S. Food and Drug Administration approval for its IntellaTip MiFi XP catheter and 501(k) clearance for its Zurpaz 8.5F steerable sheath, growing its EP mapping/ablation technology portfolio. This makes it the third major player–following both St. Jude Medical, which acquired Endosense, and GE, which invested in Acutus Medical–to […]
It’s not as simple as “Do I have a code?” A “early stage vs. late stage” panel at today’s MedTech Investing conference in Minneapolis talked about what questions they ask when determining whether payers will reimburse new products and services. Investors have to consider multiple definitions of “value,” out-of-pocket possibilities, and the possibility of shifting […]